Beta-adrenergic reactivity of erythrocytes and the progression of heart failure in patients after myocardial infarction
https://doi.org/10.15829/1560-4071-2020-1-3407
Abstract
Aim. To identify the associations between beta-adrenergic reactivity of erythrocytes and the progression of heart failure (HF) in patients after myocardial infarction (MI).
Material and methods. The study included 50 patients with HF and history of MI 6 months ago. To determine the level of sympathoadrenal system activity, we analyzed beta-adrenergic reactivity by changing the osmotic resistance of erythrocytes by use of adrenoceptor blocking agent.
Results. The frequency of HF progression after index MI was 26% (n=13). All patients were divided into 2 groups depending on the presence/absence of HF progression in the postinfarction period. When determining beta-adrenergic reactivity, it was found that patients with HF progression compared with patients without it had the higher level of beta-adrenergic reactivity of membrane (β-ARM) of erythrocytes: 58,8 (50,9; 78,0) CU and 46,8 (38,0; 66,3) CU, p=0,025). A ROC analysis made it possible to establish the β-ARM level ≥49,53 CU a cut-off point, which can be considered as a marker of HF progression in patients after MI (sensitivity 92,3%, specificity 62,2%). This level of β-ARM is associated with a more than five-fold increase of HF progression risk in patients after MI (OR 5,48; 95% CI 1,28-23,37; p=0,024).
Conclusion. In patients with HF and MI history, there is a decrease in the adrenergic reactivity of erythrocyte cell membrane, which is reflected by an increase of β-ARM above normal range of 20 CU. At the same time, β-ARM in patients with HF progression compared with patients without it is significantly increased. Established cut-off point of β-ARM (≥49,53 CU) allows predicting the HF progression with high sensitivity and specificity.
About the Authors
A. A. GarganeevaRussian Federation
Tomsk
V. A. Aleksandrenko
Russian Federation
Tomsk
E. A. Kuzheleva
Russian Federation
Tomsk
T. Yu. Rebrova
Russian Federation
Tomsk
References
1. Mareev VY, Fomin IV, Ageev FT, et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8-158. (In Russ.) doi:10.18087/cardio.2475.
2. Working Group on the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Russian Journal of Cardiology. 2017;141(1):7-81. (In Russ.) doi:10.15829/1560-4071-2017-1-7-81.
3. Beggs SAS, McDonagh TA, Gardner RS. Chronic heart failure: epidemiology, investigation and management. Medicine. 2018;46(10):594-600. doi:10.1016/j.mpmed.2018.07.006.
4. Malkova MI, Bulashova OV, Khazova EV. Specification of adrenoreactivity of an organism with adrenoreception of cell membrane in cardiovascular pathology. Practical medicine. 2013;3(13):20-3. (In Russ.)
5. Garganeeva AA, Kuzheleva EA, Aleksandrenko VA. Population study of long term outcomes of acute myocardial infarction in Tomsk. Russian Journal of Cardiology. 2017;(11):27-30. (In Russ.) doi:10.15829/15604071-2017-11-27-30.
6. Zhang DY, Anderson AS. The Sympathetic Nervous System and Heart Failure. Cardiology Clinics. 2014;32(1):33-45. doi:10.1016/j.ccl.2013.09.010.
7. de Lucia C, Piedepalumbo M, Paolisso G, at al. Sympathetic nervous system in agerelated cardiovascular dysfunction: Pathophysiology and therapeutic perspective. International Journal of Biochemistry and Cell Biology. 2019;108:29-33. doi:10.1016/j.biocel.2019.01.004.
8. Johnson JO. Autonomic Nervous System: Physiology. Pharmacology and Physiology for Anesthesia (Second Edition). 2019:137-75. ISBN: 978-1-4377-1679-5.
9. Brahmbhatt Darshan H, Cowie Martin R. Heart failure: classification and pathophysiology. Medicine. 2018;46(10):587-93. doi:10.1016/j.mpmed.2018.07.004.
10. Antoine S, Vaidya G, Imam H, et al. Pathophysiologic Mechanisms in Heart Failure: Role of the Sympathetic Nervous System. The American Journal of the Medical Sciences. 2017;353(1):27-30. doi:10.1016/j.amjms.2016.06.016.
11. Stryuk RI, Dlusskaya IG. Adrenoreactivity and cardiovascular system. M: Medicine, 2003. p. 160. (In Russ.) ISBN: 5-225-04337-2.
12. Khazova ЕV, Bulashova OV, Oslopov VN, et al. The value of determining the adrenoreactivity of the organism and polymorphisms of the β2-adrenoreceptor gene in the development of myocardial remodeling in patients with chronic heart failure. Heart failure. 2013;1(75):349. (In Russ.)
13. Horga JF, Gisbert J, De Augustin JC, et al. A beta-2-adrenergic receptor activates adenylate-cyclase in human erythrocyte membranes at physiological calcium plasma concentration. Blood Cells, Molecules and Diseases. 2000;3:223-8. doi:10.1006/bcmd.2000.0299.
14. Bulashova OV, Oslopov VN, Khazova EV, et al. Adrenoreactivity in patients with chronic heart failure. Practical medicine. 2011;4(52):72-4 (In Russ.).
15. Gazizyanova VM, Bulashova OV, Nasybullina AA, et al. Cardiopulmonary syndrome and adrenoreactivity of an organism. Kazan Medical Journal. 2016;97(6):864-9. (In Russ.) doi:10.17750/KMJ2016-864.
Review
For citations:
Garganeeva A.A., Aleksandrenko V.A., Kuzheleva E.A., Rebrova T.Yu. Beta-adrenergic reactivity of erythrocytes and the progression of heart failure in patients after myocardial infarction. Russian Journal of Cardiology. 2020;25(1):3407. https://doi.org/10.15829/1560-4071-2020-1-3407